Dupilumab (Dupixent) was approved in 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.
Dupilumab (Dupixent, Sanofi-Regeneron) is approved for the treatment of atopic dermatitis (AD) and corticosteroid-dependent or eosinophilic asthma in patients aged 12 years or older. The drug is a monoclonal antibody touted for its mechanism of blocking interleukin (IL) pathways integral to various inflammatory diseases.
Dupilumab is administered by subcutaneous injection with a 300 mg pre-filled syringe for patients with CRSwNP every other week at different injection sites. It is also approved for indications in moderate-to-severe asthma and moderate-to-severe AD.